637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I

A phase II study of eltrombopag in patients with low risk MDS and CMML harboring TET2 mutations

Maintaining higher hemoglobin levels is associated with improved overall survival in Myelodysplastic Syndromes MDS A real world retrospective analysis of electronic health records from a US community setting over the past 20 years

Trends in overall survival in MDS from 2000–2022 Have therapeutic advances made a difference

The novel allosteric NEK7 inhibit ofirnoflast HT 6184 reduces oxidized mitochondrial DNA in patients with low risk myelodysplastic syndrome

The novel allosteric NEK7 inhibitor ofirnoflast HT 6184 suppresses IL 8 and other pro inflammatory cytokines in patients with low risk myelodysplastic syndrome and symptomatic anemia

The prognostic impact of MTHFR gene polymorphisms and p15 gene methylation in Myelodysplastic Syndromes

Beyond TP53 Molecular IPSS genes multihit status revisited

Optimizing elritercept benefit risk profile by response based adaptive dosing in patients with low risk Myelodysplastic Syndromes LR MDS

EZH2 molecular alterations drive micromegakaryocyte expansion in MDS defining a specific high risk group

Better discriminative capacity of blast and blast mol scores in chronic myelomonocytic leukemia CMML

High efficacy of azacitidine combined with lenalidomide in TP53 mutation positive and other high risk myelodysplastic neoplasms

Thrombocytopenia at diagnosis adversely affects overall and leukemia free survival in lower risk MDS patients A retrospective study from the FISiM registry

LS1781 Arm E Phase II clinical trial to assess the safety and efficacy of high dose IV ascorbic acid with decitabine in newly diagnosed TET2 mutant chronic myelomonocytic leukemia CMML

Occurrence of immune mediated inflammatory disorders IMIDs during the course of myelodysplastic syndrome MDS or chronic myelomonocytic leukemia CMML negatively impacts overall survival OS A cohort based study

Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes

Long term outcomes from the randomized double blind placebo PBO controlled phase 3 imerge trial of imetelstat IME for lower risk myelodysplastic syndromes LR MDS

Chronic myelomonocytic leukemia Clinical outcomes from clinical trials submitted to the FDA over the past 25 years

The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes

MDS without clonal marker When depth outperforms breadth

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Additional myelodysplasia related genes mutations affected the clinical presentations and prognosis of patients with SRSF2 TET2 co mutations

Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes